COMMITMENTS AND CONTINGENCIES (Tables)

3 Months Ended

Mar. 31, 2013

COMMITMENTS AND CONTINGENCIES [Abstract]

Commitment payment to strategic business partners

The Company has entered into strategic business agreements for the development and marketing of finished dosage form pharmaceutical products with various pharmaceutical development companies.  Each strategic business agreement includes a future payment schedule for contingent milestone payments.  The Company will be responsible for contingent milestone payments to these strategic business partners based upon the occurrence of future events.  Each strategic business agreement defines the triggering event of its future payment schedule, such as meeting product development progress timelines, successful product testing and validation, successful clinical studies, various FDA and other regulatory approvals and other factors as negotiated in each agreement.  None of the contingent milestone payments is expected to be individually material to the Company.  These costs, when realized, will be reported as part of research and development expense in the Company's Condensed Consolidated Statement of Comprehensive Income.  As of March 31, 2013, the Company has agreements with strategic business partners committing it to pay the approximate dollar amounts listed below during the anticipated years indicated (in thousands):

Year of Payment	Amount
2013	$	6,944
2014		503
2015		198
2016		200
Total	$	7,845